At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
ZD4054 +2 moredrug
Likely dose
ZD4054 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen
In Brief
A Phase 2 clinical trial evaluating ZD4054, Pemetrexed, and 1 other intervention for Non Small Cell Lung Cancer and Lung Cancer. Completed, enrolled 66 participants across 13 sites in 5 countries.
Detailed Summary
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, Lung Cancer
CountriesBulgaria, Czechia, France, Romania, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedSep 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedSep 3, 2008
Enrollment StartAug 1, 2008
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.8 years ago
Interventions
ZD4054drug
10mg oral tablet, once daily
Pemetrexeddrug
500mg2/m IV infusion
Placebodrug
10mg oral tablet, once daily